P684: Phase 1 Study of Lp-108, a Selective BCL-2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Abstract

Background:Background: Targeting BCL-2 family proteins is a well-recognized therapeutic approach. Globally approved BCL-2 inhibitor venetoclax has shown efficacies in certain hematologic malignancies (HMs) but requires weekly ramp-up to the target dose to mitigate the risk of tumor lysis syndrome (TLS). LP-108 is a novel, highly potent, orally bioavailable, and selective BCL-2 inhibitor that has shown promising preclinical antitumor activity in various HMs.